The synergic effect of metformin and 5-aza-CdR for bladder cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26861288
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Urology
• Research Institution: Nara Medical University
• Principal Investigator: Lou Yi 奈良県立医科大学, 医学部, 研究員 (30633797)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 尿路上皮癌 / DNAメチル化 / 酸化ストレス

Outline of Final Research Achievements

In this study, I elucidated anti-tumor effects of the combination, which were 5-aza-CdR and metformin against urothelial cancer. AGEs accumulate in the cells which are exposed long term oxidant stress. I presented a hypothesis that the AGEs bind the DNA histone tails and close chromatin structures might results inhibit tumor suppressor genes such as p16 through epigenetic regulation. DNMT inhibitor, 5-aza-CdR showed anti-tumor effect for urothelial cancer in both in vivo and in vitro clearly, however the combination of 5-aza-CdR and metformin, which are inhibitor of AGEs formation did not show synergic effect. On the other hand, metformin progressed the re-expression of p16 through epigenetic regulation, that are open the chromatin.

Free Research Field

病理学